Tafamidis: A review of its use in familial amyloid polyneuropathy

Drugs

Volumn 74, Issue 12, 2014, Pages 1371-1378

  Scott, Lesley J ^a  

^a SPRINGER   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; PREALBUMIN; TAFAMIDIS; TETRAMER; BENZOXAZOLE DERIVATIVE;

ARTICLE; CLINICAL PRACTICE; DETERIORATION; DIABETIC NEUROPATHY QUESTIONNAIRE TOTAL SCORE; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FAMILIAL AMYLOID POLYNEUROPATHY; GENE MUTATION; HUMAN; OUTCOME ASSESSMENT; PERSONAL EXPERIENCE; QUALITY OF LIFE; SCORING SYSTEM; UNSPECIFIED SIDE EFFECT; ADULT; AMYLOID NEUROPATHIES, FAMILIAL;

ADULT; AMYLOID NEUROPATHIES, FAMILIAL; BENZOXAZOLES; HUMANS;

EID: 84906727945     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.1007/s40265-014-0260-2     Document Type: Article

References (18)

1. Ando Y, Coelho T, Berk JL, et al. Guideline of transthyretin-related hereditary amyloidosis for clinicians. Orphanet J Rare Dis. 2013;8:31.
2. Hou X, Aguilar M-I, Small DH. Transthyretin and familial amyloidotic polyneuropathy: recent progress in understanding the molecular mechanism of neurodegeneration. FEBS J. 2007;274(7):1637-50. (Pubitemid 46426902)
3. Planté-Bordeneuve V, Said G. Familial amyloid polyneuropathy. Lancet Neurol. 2011;10(12):1086-97.
4. Adams D, Théaudin M, Cauquil C, et al. FAP neuropathy and emerging treatments. Curr Neurol Neurosci Rep. 2014;14(3):435.
5. Merlini G, Planté-Bordeneuve V, Judge DP, et al. Effects of tafamidis on transthyretin stabilization and clinical outcomes in patients with non-Val30Met transthyretin amyloidosis. J Cardiovasc Transl Res. 2013;6(6):1011-20.
6. Nencetti S, Rossello A, Orlandini E, et al. Tafamidis (Vyndaquel): a light for FAP patients. ChemMedChem. 2014;8(10):1617-9.
7. Sekijima Y. Recent progress in the understanding and treatment of transthyretin amyloidosis. Clin Pharm Ther. 2014;39(3):225-33.
8. Bulawa CE, Connelly S, DeVit M, et al. Tafamidis, a potent and selective transthyretin kinetic stabilizer that inhibits the amyloid cascade. Proc Natl Acad Sci USA. 2012;109(24):9629-34.
9. Penchala SC, Connelly S, Wang Y, et al. AG10 inhibits amyloidogenesis and cellular toxicity of the familial amyloid cardiomyopathy-associated V122I transthyretin. Proc Natl Acad Sci USA. 2013;110(24):9992-7.
10. European Medicines Agency. Vyndaqel (tafamidis) 20 mg soft capsules: summary of product characteristics. 2013. http://www.ema.europa.eu/ema/index. jsp?curl=pages/medicines/human/medicines/002294/human-med-001498.jsp&mid= WC0b01ac058001d124. Accessed 5 May 2014.
11. Coelho T, Maia LF, da Martins Silva A, et al. Tafamidis for transthyretin familial amyloid polyneuropathy: a randomized, controlled trial. Neurology. 2012;79(8):785-92.
12. Coelho T, Maia LF, da Martins Silva A, et al. Long-term effects of tafamidis for the treatment of transthyretin familial amyloid polyneuropathy. J Neurol. 2013;260(11):2802-14.
13. Coelho T, Silva A, Maia L, et al. Long-term use of tafamidis in transthyretin familial amyloid polyneuropathy: a single center experience [abstract No. S58.005]. Neurology. 2013;80(1 Meeting Abstracts).
14. Coelho T, Conceição IM, Barroso F, et al. Long term effects of tafamidis treatment on transthyretin familial amyloid polyneuropathy (TTR-FAP): interim results of the Fx1A-303 study [abstract OS3114]. Eur J Neurol. 2014;21(Suppl 1):81.
15. Coelho T, Silva AM, Valdrez K, et al. Familial amyloid polyneuropathy treatment with tafamidis: evaluation of one year treatment in Porto, Portugal [abstract No. OP-67]. XIVth international symposium on amyloidosis; Apr 27-May 1 2014; Indianapolis, IN.
16. Damy T, Judge DP, Dogan A, et al. Cardiac safety and tolerability, and effects on cardiac function, of tafamidis in patients with non-V30M TTR-FAP [abstract No. P888]. Eur J Heart Failure. 2012;11(Suppl):S153-4.
17. Pfizer Inc. Familial amyloidosis support meeting. 2013. http://www.amyloidosissupport.org/13fam-pfizer.pdf. Accessed 5 May 2014.
18. Pfizer Inc. FDA issues complete response letter for Pfizer's tafamidis meglumine new drug application. 2012. http://www.pfizer.com/news/press-release/ press-release-archive-detail/fda-issues-complete-response-letter-for-pfizer-s- tafamidis-meglumine-new-drug-application. Accessed 5 May 2014.